Basic and clinical studies on azithromycin in respiratory infections

Hiroshi Fukuhara, Hideki Taba, Jun Inadome, Masao Tateyama, Atsushi Saito, Isamu Nakasone, Shinko Taira, Nobuchika Kusano, Seitetsu Hokama, Chotetu Hokama

Research output: Contribution to journalArticlepeer-review


We performed a basic evaluation of azithromycin (AZM), a newly developed oral macrolide antibiotic, and clinically studied its application in the treatment of respiratory infections, with the following results. 1. Antibacterial activity The minimum growth inhibitory concentrations (MICs) of AZM against 284 strains of 14 species isolated from clinical material were measured and compared with those of erythromycin (EM) roxithromycin (RXM) and clarithromycin (CAM), oral macrolides. Based on the MIC90, AZM showed similar activity to those of EM and CAM against Gram-positive bacteria, and showed the strongest activity in these macrolides against Gram-negative bacteria. 2. Clinical efficacy AZM was given to 4 patients with pneumonia, 1 patient with chronic bronchitis and 1 patient with acute bronchitis, orally at 250 or 500mg once a day for 3 days. The clinical response was excellent in 2 cases and good in 4. No adverse reactions or abnormal laboratory findings were observed.

Original languageEnglish
Pages (from-to)278-283
Number of pages6
JournalJapanese Journal of Chemotherapy
Publication statusPublished - 1995
Externally publishedYes


  • Azithromycin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Basic and clinical studies on azithromycin in respiratory infections'. Together they form a unique fingerprint.

Cite this